|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2015-07-01 |
|
作用机制GABAA receptor正向变构调节剂 |
|
|
|
|
最高研发阶段临床2/3期 |
首次获批国家/地区- |
首次获批日期- |
Phase II, multi-centered, randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety of recombinant human Epidermal Growth Factor (rhEGF) at a dose of 25 or 75 micrograms intralesionally 3 times a week for up to 12 weeks, in patients with diabetic foot ulcer (Wagner grade 1 or 2).
Pharmacokinetics in intralesional administration of recombinant Epidermal Growth Factor in patients with diabetic foot ulcers.
100 项与 Praxis Pharmaceutical SA 相关的临床结果
0 项与 Praxis Pharmaceutical SA 相关的专利(医药)
100 项与 Praxis Pharmaceutical SA 相关的药物交易
100 项与 Praxis Pharmaceutical SA 相关的转化医学